Last reviewed · How we verify
Glecaprevir and Pibrentasvir
Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, blocking viral replication.
Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, blocking viral replication. Used for Chronic hepatitis C virus infection (all genotypes 1-6), Hepatitis C in treatment-naïve and treatment-experienced patients, Hepatitis C with compensated cirrhosis.
At a glance
| Generic name | Glecaprevir and Pibrentasvir |
|---|---|
| Also known as | Direct Acting Antiviral HCV Treatment, Mavyret, G/P, Maviret |
| Sponsor | Massachusetts General Hospital |
| Drug class | Direct-acting antiviral combination (NS3/4A protease inhibitor + NS5A inhibitor) |
| Target | HCV NS3/4A protease and NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Glecaprevir is a pangenotypic NS3/4A protease inhibitor that prevents viral polyprotein processing, while pibrentasvir is an NS5A inhibitor that disrupts viral RNA replication and assembly. Together, they provide a potent combination that is effective against all major HCV genotypes with high barrier to resistance.
Approved indications
- Chronic hepatitis C virus infection (all genotypes 1-6)
- Hepatitis C in treatment-naïve and treatment-experienced patients
- Hepatitis C with compensated cirrhosis
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV (PHASE1, PHASE2)
- Feasibility and Acceptability of HCV Treatment in Pregnancy
- A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients (PHASE4)
- Rapid HCV Treatment Access for Persons Who Use Drugs (NA)
- A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus
- Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder (PHASE2, PHASE3)
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glecaprevir and Pibrentasvir CI brief — competitive landscape report
- Glecaprevir and Pibrentasvir updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI